https://orcid.org/0000-0001-6060-1228
References
- Smeele HT, Roder E, Wintjes HM, Kranenburg-van Koppen LJ, Hazes JM, Dolhain RJ. Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study.. Ann Rheum Dis. 2021;80(7):859–864. doi:10.1136/annrheumdis-2020-219547
- Ghalandari N, Kemper E, Crijns IH, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2022;81(3):402–405.
- Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–131.
- Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68(11):1793–1794.
- McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine. 1976;55(3):193–215.
- Michet CJ, McKenna CH, Luthra HS, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986;104(1):74–78.
- Kingdon J, Roscamp J, Sangle S, D’Cruz D. Relapsing polychondritis: a clinical review for rheumatologists. Rheumatology. 2018;57(9):1525–1532.
- Papo T, Wechsler B, Bletry O, Piette AM, Godeau P, Piette JC. Pregnancy in relapsing polychondritis: twenty-five pregnancies in eleven patients. Arthritis Rheum. 1997;40(7):1245–1249.
- Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299(22):1203–1207.
- Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.